Cat. No. 3066
Chemical Name: N-[1-[[(Cyanomethyl)amino]carbonyl]
Biological ActivityPotent, reversible cathepsin K inhibitor (IC50 = 0.25 nM) that displays > 4000-fold selectivity over cathepsins B, L and S. Displays reduced selectivity in cell-based assays possibly due to lysosomal accumulation. Reduces collagen breakdown and promotes bone deposition in vivo. Orally active and has intrinsic fluorescence.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Falgueyret et al (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J.Med.Chem. 48 7535. PMID: 16302795.
Palmer et al (2005) Design and synthesis of tri-ring P3 benamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J.Med.Chem. 48 7520. PMID: 16302794.
Desmarais et al (2008) Effects of cathepsin K inhibitors basicity on in vivo off-target activities. Mol.Pharmacol. 73 147. PMID: 17940194.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: L 006235, supplier, potent, selective, cathepsin, k, inhibitors, osteoporosis, fluroescent, fluorescence, L006235
Find multiple products by catalog number
New Products in this Area
Non-peptide, competitive angiotensin converting enzyme (ACE) inhibitorAprotinin
Competitive serine protease inhibitorTCID
Selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor2-MPPA
Selective glutamate carboxypeptidase II (GCP II) inhibitor; orally bioavailableE 64
Potent and irreversible cysteine protease inhibitorAEBSF
Broad spectrum, irreversible inhibitor of serine proteasesTC-E 5006
γ-secretase modulator; reduces Aβ42 levelsPTIQ
Potent MMP-3 expression inhibitor; neuroprotective
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.